184 related articles for article (PubMed ID: 23406520)
1. A highly convergent and efficient synthesis of a macrocyclic hepatitis C virus protease inhibitor BI 201302.
Wei X; Shu C; Haddad N; Zeng X; Patel ND; Tan Z; Liu J; Lee H; Shen S; Campbell S; Varsolona RJ; Busacca CA; Hossain A; Yee NK; Senanayake CH
Org Lett; 2013 Mar; 15(5):1016-9. PubMed ID: 23406520
[TBL] [Abstract][Full Text] [Related]
2. Efficient large-scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis.
Yee NK; Farina V; Houpis IN; Haddad N; Frutos RP; Gallou F; Wang XJ; Wei X; Simpson RD; Feng X; Fuchs V; Xu Y; Tan J; Zhang L; Xu J; Smith-Keenan LL; Vitous J; Ridges MD; Spinelli EM; Johnson M; Donsbach K; Nicola T; Brenner M; Winter E; Kreye P; Samstag W
J Org Chem; 2006 Sep; 71(19):7133-45. PubMed ID: 16958506
[TBL] [Abstract][Full Text] [Related]
3. Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172.
Kuethe J; Zhong YL; Yasuda N; Beutner G; Linn K; Kim M; Marcune B; Dreher SD; Humphrey G; Pei T
Org Lett; 2013 Aug; 15(16):4174-7. PubMed ID: 23919347
[TBL] [Abstract][Full Text] [Related]
4. Ring-Closing Metathesis on Commercial Scale: Synthesis of HCV Protease Inhibitor Simeprevir.
Horváth A; Depré D; A Vermeulen WA; Wuyts SL; Harutyunyan SR; Binot G; Cuypers J; Couck W; Den Heuvel DV
J Org Chem; 2019 Apr; 84(8):4932-4939. PubMed ID: 30721066
[TBL] [Abstract][Full Text] [Related]
5. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
Tsantrizos YS; Bolger G; Bonneau P; Cameron DR; Goudreau N; Kukolj G; LaPlante SR; Llinàs-Brunet M; Nar H; Lamarre D
Angew Chem Int Ed Engl; 2003 Mar; 42(12):1356-60. PubMed ID: 12671967
[No Abstract] [Full Text] [Related]
6. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.
Kong J; Chen CY; Balsells-Padros J; Cao Y; Dunn RF; Dolman SJ; Janey J; Li H; Zacuto MJ
J Org Chem; 2012 Apr; 77(8):3820-8. PubMed ID: 22458448
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp²-sp³ Suzuki-Miyaura coupling and ring closing metathesis.
Li H; Scott JP; Chen CY; Journet M; Belyk K; Balsells J; Kosjek B; Baxter CA; Stewart GW; Wise C; Alam M; Song ZJ; Tan L
Org Lett; 2015 Mar; 17(6):1533-6. PubMed ID: 25754231
[TBL] [Abstract][Full Text] [Related]
10. A convergent synthesis of the fully elaborated macrocyclic core of TMC-95A.
Coste A; Bayle A; Marrot J; Evano G
Org Lett; 2014 Mar; 16(5):1306-9. PubMed ID: 24559256
[TBL] [Abstract][Full Text] [Related]
11. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
[No Abstract] [Full Text] [Related]
12. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
Slater MJ; Amphlett EM; Andrews DM; Bamborough P; Carey SJ; Johnson MR; Jones PS; Mills G; Parry NR; Somers DO; Stewart AJ; Skarzynski T
Org Lett; 2003 Nov; 5(24):4627-30. PubMed ID: 14627400
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
[TBL] [Abstract][Full Text] [Related]
15. P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
Lampa A; Ehrenberg AE; Vema A; Åkerblom E; Lindeberg G; Danielson UH; Karlén A; Sandström A
Bioorg Med Chem; 2011 Aug; 19(16):4917-27. PubMed ID: 21782454
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
Randolph JT; Zhang X; Huang PP; Klein LL; Kurtz KA; Konstantinidis AK; He W; Kati WM; Kempf DJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2745-50. PubMed ID: 18375121
[TBL] [Abstract][Full Text] [Related]
17. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG
Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351
[TBL] [Abstract][Full Text] [Related]
18. A highly concise and convergent synthesis of HCV polymerase inhibitor Deleobuvir (BI 207127): application of a one-pot borylation-Suzuki coupling reaction.
Zhang Y; Lu BZ; Li G; Rodriguez S; Tan J; Wei HX; Liu J; Roschangar F; Ding F; Zhao W; Qu B; Reeves D; Grinberg N; Lee H; Heckmann G; Niemeier O; Brenner M; Tsantrizos Y; Beaulieu PL; Hossain A; Yee N; Farina V; Senanayake CH
Org Lett; 2014 Sep; 16(17):4558-61. PubMed ID: 25105303
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
Chen KX; Njoroge FG; Prongay A; Pichardo J; Madison V; Girijavallabhan V
Bioorg Med Chem Lett; 2005 Oct; 15(20):4475-8. PubMed ID: 16112859
[TBL] [Abstract][Full Text] [Related]
20. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
Chen KX; Njoroge FG
Prog Med Chem; 2010; 49():1-36. PubMed ID: 20855037
[No Abstract] [Full Text] [Related]
[Next] [New Search]
